SYSMED-NB

Publikationen

2023

Alborzinia, H., Z. Chen, U. Yildiz, F. P. Freitas, F. C. E. Vogel, J. P. Varga, J. Batani, C. Bartenhagen, W. Schmitz, G. Büchel, B. Michalke, J. Zheng, S. Meierjohann, E. Girardi, E. Espinet, A. F. Flórez, A. F. dos Santos, N. Aroua, T. Cheytan, J. Haenlin, L. Schlicker, T. N. X. da Silva, A. Przybylla, P. Zeisberger, G. Superti-Furga, M. Eilers, M. Conrad, M. Fabiano, U. Schweizer, M. Fischer, A. Schulze, A. Trumpp, and J. P. F. Angeli (2023). "LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma." EMBO Mol. Med. doi.org/10.15252/emmm.202318014.

Rosswog, C., J. Fassunke, A. Ernst, B. Schömig-Markiefka, S. Merkelbach-Bruse, C. Bartenhagen, M. Cartolano, S. Ackermann, J. Theissen, M. Blattner-Johnson, B. Jones, K. Schramm, J. Altmüller, P. Nürnberg, M. Ortmann, F. Berthold, M. Peifer, R. Büttner, F. Westermann, J. H. Schulte, T. Simon, B. Hero, and M. Fischer (2023). "Genomic ALK alterations in primary and relapsed neuroblastoma." Br J Cancer: 1–13. doi.org/10.1038/s41416-023-02208-y.

2022

Alborzinia, H., A. F. Florez, S. Kreth, L. M. Bruckner, U. Yildiz, M. Gartlgruber, D. I. Odoni, G. Poschet, K. Garbowicz, C. Shao, C. Klein, J. Meier, P. Zeisberger, M. Nadler-Holly, M. Ziehm, F. Paul, J. Burhenne, E. Bell, M. Shaikhkarami, R. Wurth, S. A. Stainczyk, E. M. Wecht, J. Kreth, M. Buttner, N. Ishaque, M. Schlesner, B. Nicke, C. Stresemann, M. Llamazares-Prada, J. H. Reiling, M. Fischer, I. Amit, M. Selbach, C. Herrmann, S. Wolfl, K. O. Henrich, T. Hofer, A. Trumpp, and F. Westermann (2022). "MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis." Nat Cancer 3(4): 471-485. www.ncbi.nlm.nih.gov/pubmed/35484422.

Fischer-Mertens, J., F. Otte, A. Roderwieser, C. Rosswog, Y. Kahlert, L. Werr, A.-M. Hellmann, M. Berding, B. Chiu, C. Bartenhagen, and M. Fischer (2022). "Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models." Cell Oncol: 1–13. doi.org/10.1007/s13402-022-00702-8.

Meeser, A., C. Bartenhagen, L. Werr, A.-M. Hellmann, Y. Kahlert, N. Hemstedt, P. Nürnberg, J. Altmüller, S. Ackermann, B. Hero, T. Simon, M. Peifer, M. Fischer, and C. Rosswog (2022). "Reliable assessment of telomere maintenance mechanisms in neuroblastoma." Cell Biosci 12(1): 1–16. doi.org/10.1186/s13578-022-00896-2.

2021

 

Afanasyeva, E. A., M. Gartlgruber, T. Ryl, B. Decaesteker, G. Denecker, G. Monke, U. H. Toprak, A. Florez, A. Torkov, D. Dreidax, C. Herrmann, K. Okonechnikov, S. Ek, A. K. Sharma, V. Sagulenko, F. Speleman, K. O. Henrich, and F. Westermann (2021). "Kalirin-RAC controls nucleokinetic migration in ADRN-type neuroblastoma." Life Sci Alliance 4(5). www.ncbi.nlm.nih.gov/pubmed/33658318.

Hartlieb, S. A., L. Sieverling, M. Nadler-Holly, M. Ziehm, U. H. Toprak, C. Herrmann, N. Ishaque, K. Okonechnikov, M. Gartlgruber, Y.-G. Park, E. M. Wecht, L. Savelyeva, K.-O. Henrich, C. Rosswog, M. Fischer, B. Hero, D. T. W. Jones, E. Pfaff, O. Witt, S. M. Pfister, R. Volckmann, J. Koster, K. Kiesel, K. Rippe, S. Taschner-Mandl, P. Ambros, B. Brors, M. Selbach, L. Feuerbach, and F. Westermann (2021). "Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome." Nat Commun 12(1269): 1–18. doi.org/10.1038/s41467-021-21247-8.

Jansky, S., A. K. Sharma, V. Körber, A. Quintero, U. H. Toprak, E. M. Wecht, M. Gartlgruber, A. Greco, E. Chomsky, T. G. P. Grünewald, K.-O. Henrich, A. Tanay, C. Herrmann, T. Höfer, and F. Westermann (2021). "Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma." Nat. Genet.: 1–11. doi.org/10.1038/s41588-021-00806-1.

Rosswog, C., C. Bartenhagen, A. Welte, Y. Kahlert, N. Hemstedt, W. Lorenz, M. Cartolano, S. Ackermann, S. Perner, W. Vogel, J. Altmüller, P. Nürnberg, F. Hertwig, G. Göhring, E. Lilienweiss, A. M. Stütz, J. O. Korbel, R. K. Thomas, M. Peifer, and M. Fischer (2021). "Chromothripsis followed by circular recombination drives oncogene amplification in human cancer." Nat Genet 53: 1673–1685. doi.org/10.1038/s41588-021-00951-7.

Schmelz, K., J. Toedling, M. Huska, M. C. Cwikla, L.-M. Kruetzfeldt, J. Proba, P. F. Ambros, I. M. Ambros, S. Boral, M. Lodrini, C. Y. Chen, M. Burkert, D. Guergen, A. Szymansky, K. Astrahantseff, A. Kuenkele, K. Haase, M. Fischer, H. E. Deubzer, F. Hertwig, P. Hundsdoerfer, A. G. Henssen, R. F. Schwarz, J. H. Schulte, and A. Eggert (2021). "Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions - Nature Communications." Nat Commun 12(6804): 1–13. doi.org/10.1038/s41467-021-26870-z.

2020

Cartolano, M., N. Abedpour, V. Achter, T.-P. Yang, S. Ackermann, M. Fischer, and M. Peifer (2020). "CaMuS: simultaneous fitting and de novo imputation of cancer mutational signature." Sci Rep 10(19316): 1–10. doi.org/10.1038/s41598-020-75753-8.

Gartlgruber, M., A. K. Sharma, A. Quintero, D. Dreidax, S. Jansky, Y.-G. Park, S. Kreth, J. Meder, D. Doncevic, P. Saary, U. H. Toprak, N. Ishaque, E. Afanasyeva, E. Wecht, J. Koster, R. Versteeg, T. G. P. Grünewald, D. T. W. Jones, S. M. Pfister, K.-O. Henrich, J. van Nes, C. Herrmann, and F. Westermann (2020). "Super enhancers define regulatory subtypes and cell identity in neuroblastoma." Nat Cancer: 1–15. doi.org/10.1038/s43018-020-00145-w.

Gualandi, M., M. Iorio, O. Engeler, A. Serra-Roma, G. Gasparre, J. H. Schulte, D. Hohl, and O. Shakhova (2020). "Oncogenic ALK(F1174L) drives tumorigenesis in cutaneous squamous cell carcinoma." Life Sci Alliance 3(6). doi.org/10.26508/lsa.201900601.

Kuchen, E. E., N. B. Becker, N. Claudino, and T. Hofer (2020). "Hidden long-range memories of growth and cycle speed correlate cell cycles in lineage trees." Elife 9: 25. www.ncbi.nlm.nih.gov/pubmed/31971512.

Thole, T. M., J. Toedling, A. Sprussel, S. Pfeil, L. Savelyeva, D. Capper, C. Messerschmidt, D. Beule, S. Groeneveld-Krentz, C. Eckert, G. Gambara, A. G. Henssen, S. Finkler, J. H. Schulte, A. Sieber, N. Bluethgen, C. R. A. Regenbrecht, A. Kunkele, M. Lodrini, A. Eggert, and H. E. Deubzer (2020). "Reflection of neuroblastoma intratumor heterogeneity in the new OHC-NB1 disease model." Int J Cancer 146(4): 1031-1041. www.ncbi.nlm.nih.gov/pubmed/31304977.

Tjaden, B., K. Baum, V. Marquardt, M. Simon, M. Trajkovic-Arsic, T. Kouril, B. Siebers, J. Lisec, J. T. Siveke, J. H. Schulte, U. Benary, M. Remke, J. Wolf, and A. Schramm (2020). "N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma." Sci Rep 10(7157): 1–10. doi.org/10.1038/s41598-020-64040-1.

Yang, C.-L., A. Serra-Roma, M. Gualandi, N. Bodmer, F. Niggli, J. H. Schulte, P. K. Bode, and O. Shakhova (2020). "Lineage-restricted sympathoadrenal progenitors confer neuroblastoma origin and its tumorigenicity." Oncotarget 11(24): 2357–2371. doi.org/10.18632/oncotarget.27636.

2019

Ackermann, S. and Fischer, M. (2019). "Telomere Maintenance in Pediatric Cancer." Int J Mol Sci 20(23). www.ncbi.nlm.nih.gov/pubmed/31757062.

Baum, K., Schuchhardt, J., Wolf, J. and Busse, D. (2019). "Of Gene Expression and Cell Division Time: A Mathematical Framework for Advanced Differential Gene Expression and Data Analysis." Cell Syst. www.ncbi.nlm.nih.gov/pubmed/31521604.

Campbell, K., Shyr, D., Bagatell, R., Fischer, M., Nakagawara, A., Nieto, A. C., Brodeur, G. M., Matthay, K. K., London, W. B. and DuBois, S. G. (2019). "Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project." Pediatr Blood Cancer 66(8): e27819. www.ncbi.nlm.nih.gov/pubmed/31115156.

Jachimowicz, R. D., Beleggia, F., Isensee, J., Velpula, B. B., Goergens, J., Bustos, M. A., Doll, M. A., Shenoy, A., Checa-Rodriguez, C., Wiederstein, J. L., Baranes-Bachar, K., Bartenhagen, C., Hertwig, F., Teper, N., Nishi, T., Schmitt, A., Distelmaier, F., Lüdecke, H.-J., Albrecht, B., Krüger, M., Schumacher, B., Geiger, T., Hoon, D. S. B., Huertas, P., Fischer, M., Hucho, T., Peifer, M., Ziv, Y., Reinhardt, H. C., Wieczorek, D. and Shiloh, Y. (2019). "UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors." Cell. www.ncbi.nlm.nih.gov/pubmed/30612738.

Körber, V. and Höfer, T. (2019). "Inferring growth and genetic evolution of tumors from genome sequences." Current Opinion in Systems Biology 16: 1--9. www.sciencedirect.com/science/article/pii/S2452310019300344.

Korber, V., Yang, J., Barah, P., Wu, Y., Stichel, D., Gu, Z., Fletcher, M. N. C., Jones, D., Hentschel, B., Lamszus, K., Tonn, J. C., Schackert, G., Sabel, M., Felsberg, J., Zacher, A., Kaulich, K., Hubschmann, D., Herold-Mende, C., von Deimling, A., Weller, M., Radlwimmer, B., Schlesner, M., Reifenberger, G., Hofer, T. and Lichter, P. (2019). "Evolutionary Trajectories of IDH(WT) Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis." Cancer Cell. www.ncbi.nlm.nih.gov/pubmed/30905762.

2018

Ackermann, S., Cartolano, M., Hero, B., Welte, A., Kahlert, Y., Roderwieser, A., Bartenhagen, C., Walter, E., Gecht, J., Kerschke, L., Volland, R., Menon, R., Heuckmann, J. M., Gartlgruber, M., Hartlieb, S., Henrich, K.-O., Okonechnikov, K., Altmüller, J., Nürnberg, P., Lefever, S., Wilde, B. d., Sand, F., Ikram, F., Rosswog, C., Fischer, J., Theissen, J., Hertwig, F., Singhi, A. D., Simon, T., Vogel, W., Perner, S., Krug, B., Schmidt, M., Rahmann, S., Achter, V., Lang, U., Vokuhl, C., Ortmann, M., Büttner, R., Eggert, A., Speleman, F., O’Sullivan, R. J., Thomas, R. K., Berthold, F., Vandesompele, J., Schramm, A., Westermann, F., Schulte, J. H., Peifer, M.Fischer, M., 2018. A mechanistic classification of clinical phenotypes in neuroblastoma. Science, 362(6419), 1165-1170. doi.org/10.1126/science.aat6768

Correia, M. P., Stojanovic, A., Bauer, K., Juraeva, D., Tykocinski, L.-O., Lorenz, H.-M., Brors, B.Cerwenka, A., 2018. Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential. Proc. Natl. Acad. Sci. U.S.A., 115(26), E5980-E5989. doi.org/10.1073/pnas.1720564115

De Wilde, B., Beckers, A., Lindner, S., Kristina, A., De Preter, K., Depuydt, P., Mestdagh, P., Sante, T., Lefever, S., Hertwig, F., Peng, Z., Shi, L. M., Lee, S., Vandermarliere, E., Martens, L., Menten, B., Schramm, A., Fischer, M., Schulte, J., Vandesompele, J.Speleman, F., 2018. The mutational landscape of MYCN, Lin28b and ALK(F1174L) driven murine neuroblastoma mimics human disease. Oncotarget, 9(9), 8334-8349. doi.org/10.18632/oncotarget.23614

Depuydt, P., Boeva, V., Hocking, T. D., Cannoodt, R., Ambros, I. M., Ambros, P. F., Asgharzadeh, S., Attiyeh, E. F., Combaret, V., Defferrari, R., Fischer, M., Hero, B., Hogarty, M. D., Irwin, M. S., Koster, J., Kreissman, S., Ladenstein, R., Lapouble, E., Laureys, G., London, W. B., Mazzocco, K., Nakagawara, A., Noguera, R., Ohira, M., Park, J. R., Potschger, U., Theissen, J., Tonini, G. P., Valteau-Couanet, D., Varesio, L., Versteeg, R., Speleman, F., Maris, J. M., Schleiermacher, G.De Preter, K., 2018. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. J Natl Cancer Inst, 110(10), 1084-1093. doi.org/10.1093/jnci/djy022

Meder, L., König, K., Dietlein, F., Macheleidt, I., Florin, A., Ercanoglu, M. S., Rommerscheidt-Fuss, U., Koker, M., Schön, G., Odenthal, M., Klein, F., Büttner, R., Schulte, J. H., Heukamp, L. C.Ullrich, R. T., 2018. LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model. Oncogene, 37(20), 2746-2756. doi.org/10.1038/s41388-018-0158-7

2017

Benary, U., Wolf, E.Wolf, J., 2017. Mathematical modelling of promoter occupancies in MYC-dependent gene regulation. Genomics and Computational Biology, 3(2), 54. doi.org/10.18547/gcb.2017.vol3.iss2.e54

Henssen, A. G., Odersky, A., Szymansky, A., Seiler, M., Althoff, K., Beckers, A., Speleman, F., Schäfers, S., De Preter, K., Astrahanseff, K., Struck, J., Schramm, A., Eggert, A., Bergmann, A.Schulte, J. H., 2017. Targeting tachykinin receptors in neuroblastoma. Oncotarget, 8(1), 430-443. doi.org/10.18632/oncotarget.13440

Rosswog, C., Schmidt, R., Oberthuer, A., Juraeva, D., Brors, B., Engesser, A., Kahlert, Y., Volland, R., Bartenhagen, C., Simon, T., Berthold, F., Hero, B., Faldum, A.Fischer, M., 2017. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment. Neoplasia, 19(12), 982-990. doi.org/10.1016/j.neo.2017.09.006

Ryl, T., Kuchen, E. E., Bell, E., Shao, C., Flórez, A. F., Mönke, G., Gogolin, S., Friedrich, M., Lamprecht, F., Westermann, F.Höfer, T., 2017. Cell-Cycle Position of Single MYC-Driven Cancer Cells Dictates Their Susceptibility to a Chemotherapeutic Drug. Cell Syst, 5(3), 237-250.e8. doi.org/10.1016/j.cels.2017.07.005

Shao, C.Hofer, T., 2017. Robust classification of single-cell transcriptome data by nonnegative matrix factorization. Bioinformatics, 33(2), 235-242. doi.org/10.1093/bioinformatics/btw607

Thole, T. M., Lodrini, M., Fabian, J., Wuenschel, J., Pfeil, S., Hielscher, T., Kopp-Schneider, A., Heinicke, U., Fulda, S., Witt, O., Eggert, A., Fischer, M.Deubzer, H. E., 2017. Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. Cell Death Dis, 8(3), e2635. doi.org/10.1038/cddis.2017.49

2016

Althoff, K., Schulte, J. H.Schramm, A., 2016. Towards diagnostic application of non-coding RNAs in neuroblastoma. Expert Rev. Mol. Diagn., 16(12), 1307-1313. doi.org/10.1080/14737159.2016.1256207

Eccles, R. L., Czajkowski, M. T., Barth, C., Müller, P. M., McShane, E., Grunwald, S., Beaudette, P., Mecklenburg, N., Volkmer, R., Zühlke, K., Dittmar, G., Selbach, M., Hammes, A., Daumke, O., Klussmann, E., Urbé, S.Rocks, O., 2016. Bimodal antagonism of PKA signalling by ARHGAP36. Nat Commun, 7, 12963. doi.org/10.1038/ncomms12963

Fabian, J., Opitz, D., Althoff, K., Lodrini, M., Hero, B., Volland, R., Beckers, A., de Preter, K., Decock, A., Patil, N., Abba, M., Kopp-Schneider, A., Astrahantseff, K., Wunschel, J., Pfeil, S., Ercu, M., Kunkele, A., Hu, J., Thole, T., Schweizer, L., Mechtersheimer, G., Carter, D., Cheung, B. B., Popanda, O., von Deimling, A., Koster, J., Versteeg, R., Schwab, M., Marshall, G. M., Speleman, F., Erb, U., Zoeller, M., Allgayer, H., Simon, T., Fischer, M., Kulozik, A. E., Eggert, A., Witt, O., Schulte, J. H.Deubzer, H. E., 2016. MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget, 7(41), 66344-66359. doi.org/10.18632/oncotarget.11662

Formicola, D., Petrosino, G., Lasorsa, V. A., Pignataro, P., Cimmino, F., Vetrella, S., Longo, L., Tonini, G. P., Oberthuer, A., Iolascon, A., Fischer, M.Capasso, M., 2016. An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma. J Transl Med, 14(1), 142. doi.org/10.1186/s12967-016-0896-7

Henrich, K. O., Bender, S., Saadati, M., Dreidax, D., Gartlgruber, M., Shao, C., Herrmann, C., Wiesenfarth, M., Parzonka, M., Wehrmann, L., Fischer, M., Duffy, D. J., Bell, E., Torkov, A., Schmezer, P., Plass, C., Hofer, T., Benner, A., Pfister, S. M.Westermann, F., 2016. Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas. Cancer Res, 76(18), 5523-37. doi.org/10.1158/0008-5472.CAN-15-2507

Henssen, A., Althoff, K., Odersky, A., Beckers, A., Koche, R., Speleman, F., Schäfers, S., Bell, E., Nortmeyer, M., Westermann, F., De Preter, K., Florin, A., Heukamp, L., Spruessel, A., Astrahanseff, K., Lindner, S., Sadowski, N., Schramm, A., Astorgues-Xerri, L., Riveiro, M. E., Eggert, A., Cvitkovic, E.Schulte, J. H., 2016. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. Clin. Cancer Res., 22(10), 2470-2481. doi.org/10.1158/1078-0432.CCR-15-1449

Ikram, F., Ackermann, S., Kahlert, Y., Volland, R., Roels, F., Engesser, A., Hertwig, F., Kocak, H., Hero, B., Dreidax, D., Henrich, K.-O., Berthold, F., Nürnberg, P., Westermann, F.Fischer, M., 2016. Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma. Mol Oncol, 10(2), 344-359. doi.org/10.1016/j.molonc.2015.10.020

Lodrini, M., Poschmann, G., Schmidt, V., Wünschel, J., Dreidax, D., Witt, O., Höfer, T., Meyer, H. E., Stühler, K., Eggert, A.Deubzer, H. E., 2016. Minichromosome Maintenance Complex Is a Critical Node in the miR-183 Signaling Network of MYCN-Amplified Neuroblastoma Cells. J. Proteome Res., 15(7), 2178-2186. doi.org/10.1021/acs.jproteome.6b00134

Lorenzin, F., Benary, U., Baluapuri, A., Walz, S., Jung, L. A., Eyss, B. v., Kisker, C., Wolf, J., Eilers, M.Wolf, E., 2016. Different promoter affinities account for specificity in MYC-dependent gene regulation. Elife, 5, e15161. doi.org/10.7554/eLife.15161

Ribeiro, D., Klarqvist, M. D. R., Westermark, U. K., Oliynyk, G., Dzieran, J., Kock, A., Savatier Banares, C., Hertwig, F., Johnsen, J. I., Fischer, M., Kogner, P., Lovén, J.Arsenian Henriksson, M., 2016. Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients. Cell Rep, 16(4), 979-993. doi.org/10.1016/j.celrep.2016.06.052

Thompson, D., Vo, K. T., London, W. B., Fischer, M., Ambros, P. F., Nakagawara, A., Brodeur, G. M., Matthay, K. K.DuBois, S. G., 2016. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer, 122(6), 935-945. doi.org/10.1002/cncr.29848

 

2015

Carter, D.R., Murray, J., Cheung, B.B., Gamble, L., Koach, J., Tsang, J., Sutton, S., Kalla, H., Syed, S., Gifford, A.J., Issaeva, N., Biktasova, A., Atmadibrata, B., Sun, Y., Sokolowski, N., Ling, D., Kim, P.Y., Webber, H., Clark, A., Ruhle, M., Liu, B., Oberthuer, A., Fischer, M., Byrne, J., Saletta, F., Thwe, L.M., Purmal, A., Haderski, G., Burkhart, C., Speleman, F., De Preter, K., Beckers, A., Ziegler, D.S., Liu, T., Gurova, K.V., Gudkov, A.V., Norris, M.D., Haber, M., Marshall, G.M., 2015. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci Transl Med 7, 312ra176. doi.org/10.1126/scitranslmed.aab1803

Fey, D., Halasz, M., Dreidax, D., Kennedy, S.P., Hastings, J.F., Rauch, N., Munoz, A.G., Pilkington, R., Fischer, M., Westermann, F., Kolch, W., Kholodenko, B.N., Croucher, D.R., 2015. Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. Sci Signal 8, ra130. doi.org/10.1126/scisignal.aab0990

Lindner, S., Bachmann, H.S., Odersky, A., Schaefers, S., Klein-Hitpass, L., Hero, B., Fischer, M., Eggert, A., Schramm, A., Schulte, J.H., 2015. Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. Biomed Rep 3, 443–446. doi.org/10.3892/br.2015.463

Peifer, M., Hertwig, F., Roels, F., Dreidax, D., Gartlgruber, M., Menon, R., Krämer, A., Roncaioli, J.L., Sand, F., Heuckmann, J.M., Ikram, F., Schmidt, R., Ackermann, S., Engesser, A., Kahlert, Y., Vogel, W., Altmüller, J., Nürnberg, P., Thierry-Mieg, J., Thierry-Mieg, D., Mariappan, A., Heynck, S., Mariotti, E., Henrich, K.-O., Gloeckner, C., Bosco, G., Leuschner, I., Schweiger, M.R., Savelyeva, L., Watkins, S.C., Shao, C., Bell, E., Höfer, T., Achter, V., Lang, U., Theissen, J., Volland, R., Saadati, M., Eggert, A., de Wilde, B., Berthold, F., Peng, Z., Zhao, C., Shi, L., Ortmann, M., Büttner, R., Perner, S., Hero, B., Schramm, A., Schulte, J.H., Herrmann, C., O’Sullivan, R.J., Westermann, F., Thomas, R.K., Fischer, M., 2015. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 526, 700–704. doi.org/10.1038/nature14980

Schramm, A., Köster, J., Assenov, Y., Althoff, K., Peifer, M., Mahlow, E., Odersky, A., Beisser, D., Ernst, C., Henssen, A.G., Stephan, H., Schröder, C., Heukamp, L., Engesser, A., Kahlert, Y., Theissen, J., Hero, B., Roels, F., Altmüller, J., Nürnberg, P., Astrahantseff, K., Gloeckner, C., De Preter, K., Plass, C., Lee, S., Lode, H.N., Henrich, K.-O., Gartlgruber, M., Speleman, F., Schmezer, P., Westermann, F., Rahmann, S., Fischer, M., Eggert, A., Schulte, J.H., 2015. Mutational dynamics between primary and relapse neuroblastomas. Nat. Genet. 47, 872–877. doi.org/10.1038/ng.3349

 

SYSMED-NB-Projekte in den Medien:

Diese Seite nutzt Website Tracking-Technologien von Dritten, um ihre Dienste anzubieten. Ich bin damit einverstanden und kann meine Einwilligung jederzeit mit Wirkung für die Zukunft widerrufen oder ändern.

Einstellungen Akzeptieren ImpressumDatenschutz